Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (October 2023)
16 slides from Argenica Therapeutics's investor presentation, October 2023
Slide 1: Investor Presentation
INVESTOR ARGENICA THERAPEUTICS PRESENTATION ASX: AGN OCTOBER 2023 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Introduction to Argenica
INTRODUCTION TO ARGENICA NOVEL A NEW FRONTIER TARGETING MULTIPLE NEUROPROTECTIVE IN MEDICINE INDICATIONS TREATMENTS STROKE PHASE 2 ARGENICA THERAPEUTICS ARG-007 There are no marketed drugs that Argenica’s novel protect the brain after stroke SIS2 PHASE 2 neuroprotective drug ARG-007 aims to fill thi
Slide 4: Key Company Metrics
KEY COMPANY METRICS $9.3M +$4M R&D REFUND EXPECTED CASH @ BANK1 NON-DILUTIVE GRANTS2 Q4 CY23 ARGENICA THERAPEUTICS 98.3M $34M FUNDED SHARES ON ISSUE MARKET CAP3 TO COMMENCE PHASE 2 1. Cash balance as @ 30 June 2023 2. Various ASX Announcements dated 20 January 2023, 22 March 2023, 30 March 2023, 12
Slide 5: The Devastating Impact of Stroke
THE DEVASTATING IMPACT OF STROKE INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS ONE IN FOUR ONLY 10% 1.9 MILLION people will suffer a will recover almost brain cells are attacked each stroke in their lifetime1 completely, due to the extent minute during a stroke2 of bra
Slide 6: ARG-007 Could Provide a Solution
ARG-007 COULD PROVIDE A SOLUTION ARG-007 HOW IT WORKS ISCHEMIC STROKE EXAMPLE Cationic poly-arginine peptide INITIAL INFARCTION (STROKE) SETS 1 OFF A CASCADE OF CELL DEATH ARGENICA THERAPEUTICS Multiple mechanisms of action Granted patents & strong IP CELL DEATH WILL CONTINUE 2 SPREADING FROM LOCATI
Slide 7: Implications for Stroke Patients
IMPLICATIONS FOR STROKE PATIENTS REDUCTION IN REDUCTION IN CELL DEATH RECOVERY TIME OPTIONS FOR ARG-007 ADMINISTRATION ARGENICA THERAPEUTICS PATIENT HAS PATIENT IN ARRIVES AT DIAGNOSE TREATMENT AMBULANCE HOSPITAL STROKE TYPE PLAN REHAB BEGINS A STROKE Point of care intervention Alternatively, can be
Slide 8: The Ideal Stroke Therapeutic
THE IDEAL STROKE THERAPEUTIC PREVIOUS BARRIERS FOR WHAT SETS NEUROPROTECTIVE DRUGS ARG-007 APART Do not fit into current standard of care ARG-007 has multi-functional ARGENICA THERAPEUTICS mechanisms of action Past drugs focused on targeting singular Has shown significant efficacy in different mecha
Slide 9: Encouraging Results to Date
ENCOURAGING RESULTS TO DATE PRE-CLINICAL (ANIMAL STUDIES) SUCCESSFUL PHASE 1 (HUMAN STUDY) 70 PERCENT CAN BE Doses of ARG-007 proved safe and well- REDUCTION ADMINISTERED tolerated in healthy human Phase 1 IN BRAIN WITH CLOT No serious adverse events were detected TISSUE DEATH DISSOLVING ARGENICA TH
Slide 10: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE NEAR TERM Q3 Q4 Q1 Q2 OVERVIEW TIMELINE CY23 CY23 CY24 CY24 Up to 10 Australian hospitals Pre-IND FDA meeting Double-blinded, randomised, ARGENICA THERAPEUTICS Ethics approval placebo-controlled study Hospital site start-up ARG-007 will be given to patients that have
Slide 11: Phase 2 Protocol
PHASE 2 PROTOCOL ASSESSMENT INCLUSION CRITERIA RANDOMISED INTO TRIAL CLOT REMOVAL RECOVERY ARG-007 Scanning and Large vessel Mechanical Monitoring of diagnosis of stroke occlusion (LVO) removal of clot the patient type in hospital stroke in the brain Placebo ARGENICA THERAPEUTICS Diagnosed LVO strok
Slide 12: Post Phase 2 Strategy
POST PHASE 2 STRATEGY ESTIMATED TIMELINE FOR LICENSING OR PARTNERING: COMPLETION OF PHASE 2 If the Phase 2 trial shows promising results, Argenica may license ARG-007 for stroke to a larger pharmaceutical group that has the resources to carry out larger Phase 3 trials and commercialisation Final tri
Slide 13: Pipeline of Additional Indications
PIPELINE OF ADDITIONAL INDICATIONS TRAUMATIC BRAIN ALZHEIMER’S HYPOXIC-ISCHAEMIC INJURY DISEASE ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS Estimated USD$18.6bn Alzheimer’s therapeutics HIE occurs in 1.5 to 2.5 market size by 20311 market USD$13bn by 20314 births per 10007 Preclinical data shows ARG-
Slide 14: Developing Different Administration Routes
TABLETS, NASAL SPRAYS OR EPIPEN STYLE Preferable for chronic conditions requiring ongoing neuroprotective treatment: DEVELOPING DIFFERENT ADMINISTRATION ROUTES ARGENICA THERAPEUTICS ALZHEIMER’S MILD TBI Awarded $419,000 in non-dilutive grant funding under the Western Australian government's Innovati
Slide 15: Investment Highlights
INVESTMENT HIGHLIGHTS EXPERIENCED WORKING WITH PHASE 2 ETHICS BIOTECH TEAM WORLD LEADING APPROVED EXPERTS ARGENICA THERAPEUTICS OPPORTUNITY IN MULTIPLE ACCESSED TARGETING LARGE APPLICATIONS NON-DILUTIVE ADDRESSABLE & PIPELINE FUNDING MARKETS 15 www.argenica.com.au
Slide 16: Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 16 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (October 2023) on 6ix